Clinical study of Perioperative Use of Levosimendan in Patients Undergoing Heart Valve Replacement

Simple item page
dc.contributor.authorHuang, Jiawenen_US
dc.contributor.authorHuang, Chengfengen_US
dc.contributor.authorLin, Zhaomingen_US
dc.contributor.authorZhang, Zhidongen_US
dc.date.accessioned2020-11-18T10:29:11Z
dc.date.available2020-11-18T10:29:11Z
dc.date.issued2020-04
dc.description.abstractObjective To investigate the clinical effect of levosimendan in perioperative aortic and/or mitral valvereplacement. Methods Patients undergoing open heart aortic and/or mitral valve replacement in our hospitalfrom January 2018 to December 2019 were enrolled. 45 patients in the control group received routineperioperative treatment based on dopamine, while 45 patients in the research group received continuousperioperative administration of levosimendan injection for 24h on the basis of routine treatment. The leftventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDd) and left ventricular end-systolicdiameter (LVDs) were evaluated by color doppler echocardiography before and one week after surgery.Postoperative mechanical ventilation weaning time, length of ICU stays, number of vasoactive drugs used andwithdrawal time; indexes of liver and kidney function before and on the day after surgery to 10 days after surgery;use of in vitro support techniques such as aortic balloon pulsation (IABP), continuous renal replacement therapy(CRRT) and extracorporeal membrane oxygenation (ECMO) within 5 days of perioperative period. Results Theimprovement of LVDs and LVEF in the study group using levosimendan one week after the operation wassignificantly better than that in the control group (P value was 0.013 and 0.001, respectively), and fewer kinds ofvasoactive drugs were needed (P<0.001), and the risk of postoperative AKI in the study group was significantlylower than that in the control group (P=0.047). Conclusion The perioperative use of levosimendan can effectivelypromote the recovery of cardiac systolic function and reduce the risk of postoperative AKI.en_US
dc.identifier.affiliationsDepartment of Pharmacy, First Affiliated Hospital, Jinan University, Guangzhou 510630, Chinaen_US
dc.identifier.affiliationsDepartment of Cardiovascular Surgery, First Affiliated Hospital, Jinan University, Guangzhou 510630, Chinaen_US
dc.identifier.citationHuang Jiawen, Huang Chengfeng, Lin Zhaoming, Zhang Zhidong. Clinical study of Perioperative Use of Levosimendan in Patients Undergoing Heart Valve Replacement. Journal of Pharmaceutical and Biomedical Sciences. 2020 Apr; 10(4): 65-72en_US
dc.identifier.issn2230-7885
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/215715
dc.languageenen_US
dc.publisherLawarence Press Pvt. Ltd.en_US
dc.relation.issuenumber4en_US
dc.relation.volume10en_US
dc.source.urihttps://lawarencepress.com/ojs/index.php/JPBMS/article/view/608/pdf_291en_US
dc.subjectLevosimendanen_US
dc.subjectCardiac valve replacementen_US
dc.subjectAortic valve replacementen_US
dc.subjectMitral valve replacementen_US
dc.subjectPerioperativeen_US
dc.titleClinical study of Perioperative Use of Levosimendan in Patients Undergoing Heart Valve Replacementen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jpbms2020v10n4p65.pdf
Size:
1.17 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmaceutical and Biomedical Sciences